Statins and congenital malformations: cohort study

DSpace/Manakin Repository

Statins and congenital malformations: cohort study

Citable link to this page

 

 
Title: Statins and congenital malformations: cohort study
Author: Bateman, Brian T; Hernandez-Diaz, Sonia; Fischer, Michael A; Seely, Ellen W; Ecker, Jeffrey L; Franklin, Jessica M; Desai, Rishi J; Allen-Coleman, Cora; Mogun, Helen; Avorn, Jerry; Huybrechts, Krista F

Note: Order does not necessarily reflect citation order of authors.

Citation: Bateman, B. T., S. Hernandez-Diaz, M. A. Fischer, E. W. Seely, J. L. Ecker, J. M. Franklin, R. J. Desai, et al. 2015. “Statins and congenital malformations: cohort study.” BMJ : British Medical Journal 350 (1): h1035. doi:10.1136/bmj.h1035. http://dx.doi.org/10.1136/bmj.h1035.
Full Text & Related Files:
Abstract: Objective: To examine the teratogenic potential of statins. Design: Cohort study. Setting: United States. Participants: A cohort of 886 996 completed pregnancies linked to liveborn infants of women enrolled in Medicaid from 2000 to 2007. Methods: We examined the risk of major congenital malformations and organ specific malformations in offspring associated with maternal use of a statin in the first trimester. Propensity score based methods were used to control for potential confounders, including maternal demographic characteristics, obstetric and medical conditions, and use of other drugs. Results: 1152 (0.13%) women used a statin during the first trimester. In unadjusted analyses, the prevalence of malformations in the offspring of these women was 6.34% compared with 3.55% in those of women who did not use a statin in the first trimester (relative risk 1.79, 95% confidence interval 1.43 to 2.23). Controlling for confounders, particularly pre-existing diabetes, accounted for this increase in risk (1.07, 0.85 to 1.37). There were also no statistically significant increases in any of the organ specific malformations assessed after accounting for confounders. Results were similar across a range of sensitivity analyses. Conclusions: Our analysis did not find a significant teratogenic effect from maternal use of statins in the first trimester. However, these findings need to be replicated in other large studies, and the long term effects of in utero exposure to statins needs to be assessed, before use of statins in pregnancy can be considered safe.
Published Version: doi:10.1136/bmj.h1035
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362473/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351064
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters